期刊文献+

Study on the mechanism of"Sangu Decoction"in the treatment of bone metastatic carcinoma

下载PDF
导出
摘要 Objective:To study the mechanism of"Sangu Decoction"in the treatment of bone metastatic carcinoma by network pharmacology.Methods:TCMSP,TCMID and TCM Database@Taiwan databases and literature search were used to screen the main effective components of drugs.Swiss Target and TCMSP databases were used to search the potential therapeutic targets of"Sangu Decoction".DisGeNet and Drugbank databases were used to search the genes of bone metastatic carcinoma.Drug action targets and disease genes were mapped.Cytoscape 3.8.1 software was used to visualize and screen out the core genes.GO and KEGG pathway analysis was performed on potential therapeutic targets.Results:There were 29 main active ingredients in"Sangu Decoction",which contained 413 target proteins.There are 773 disease targets of bone metastatic carcinoma,of which 112 are potential targets of"Sangu Decoction"for the treatment of bone metastatic carcinoma.Through GO and KEGG pathway analysis,it was found that"Sangu Decoction"exerted anti-cancer,inhibiting bone metastasis and immune regulation mechanism through TNF,ErbB,FoxO,PI3K-Akt,Toll-like Receptor,NOD-like Receptor,Rap1 and other signaling pathways in the treatment of bone metastatic carcinoma.The key genes of"Sangu Decoction"in treating bone metastatic carcinoma are VEGFA,AKT1,IL6,TP53,MAPK3,SRC,EGFR and CASP3 and so on.Conclusion:In this study,we constructed a a multi-level interaction"traditional Chinese medicine-compound-target-pathway"network through network pharmacology,and found that the mechanism of"Sangu Decoction"in the treatment of bone metastasis cancer involves multiple targets and pathways,which may be related to anti-cancer,inhibition of bone metastasis,regulation of immunity and so on.
出处 《Journal of Hainan Medical University》 2022年第8期45-50,共6页 海南医学院学报(英文版)
基金 General Program of National Natural Science Foundation of China(No.81973640)。
  • 相关文献

参考文献3

二级参考文献11

  • 1Clohisy D R,Mantyh P W.Bone cancer pain.Cancer,2003,97 (Suppl3):866-873.
  • 2Rosen L S,Gordon D H,Dugan W J,et al.Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer,2004,100(1):36-43.
  • 3Portenoy R K,Lesage P.Management of cancer pain.Lancet, 1999,353(65):1695-1700.
  • 4Medhurst S J,Walker K,Bowes M,et al.A rat model of bone cancer pain.Pain,2002,96(1-2): 129-140.
  • 5Walker K,Medhurst S J,Kidd B L,et al.Disease modifying and anti-nociceptive effects of the bisphosphonate,zoledronic acid in a model of bone cancer pain.Pain,2002,100(3):2 t 9-229.
  • 6Livak K J,Schmittgen T D.Analysis of Relative gene expression data using real-time quantitative PCR and the 2-A ACT Method. Methods ,2001,25 (4):402-408.
  • 7Shaomian Yao,Fenghui Pan,Gary E.Wise.Chronological gene expression of parathyroid hormone-related protein(PTHrP) in the stellate reticulum of the rat-implications for tooth eruption.archives of oral biology,2007(52):228-232.
  • 8James Deschner,Ewa Wypasek,Mario Ferretti,et al.Regulation of RANKL by biomechanical loading in fibrochondrocytes of meniscus.Journal of Biomechanics,2006 (39): 1796-1803.
  • 9Hiraga T,Myoui A,Choi M E,et al.Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor- β enhances bone metastases in breast cancer.Cancer Res,2006,66(4):2067- 2073.
  • 10Siclari V A,Guise T A,Chirgwin J M.Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases.Cancer Metastasis Rev,2006,25(4):621-633.

共引文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部